CMS Proposes Letting Part D Plans Switch Biologics To Non-Interchangeable Biosimilars

In a bid to boost uptake of lower-cost biosimilars, CMS is proposing to let Medicare Part D plans substitute reference biologics with biosimilars that haven’t been deemed interchangeable by FDA. Currently, reference products can only be substituted with interchangeable biosimilars. The proposed shift, outlined in the contract year 2025 Medicare Advantage and Part D policies proposed by CMS Monday (Nov. 6), would apply to all plan enrollees, including those already taking the reference product before the change takes effect, following...